Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine. by von Mollendorf, C et al.
Vaccine xxx (xxxx) xxxContents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc inePneumococcal carriage in children in Ulaanbaatar, Mongolia before and
one year after the introduction of the 13-valent pneumococcal conjugate
vaccinehttps://doi.org/10.1016/j.vaccine.2019.05.078
0264-410X/ 2019 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Murdoch Children’s Research Institute, The Royal
Children’s Hospital, 50 Flemington Road, Parkville, Victoria 3052, Australia.
E-mail address: claire.vonmollendorf@mcri.edu.au (C. von Mollendorf).
1 Present address: RhEACH, Level 1, Rue de la Cité 1, Geneva.
2 Contributed equally.
Please cite this article as: C. von Mollendorf, E. M. Dunne, S. La Vincente et al., Pneumococcal carriage in children in Ulaanbaatar, Mongolia before a
year after the introduction of the 13-valent pneumococcal conjugate vaccine, Vaccine, https://doi.org/10.1016/j.vaccine.2019.05.078Claire von Mollendorf a,b,⇑, Eileen M. Dunne a,b, Sophie La Vincente a,1, Mukhchuluun Ulziibayar c,
Bujinlkham Suuri c, Dashtseren Luvsantseren c, Dorj Narangerel d, Belinda D. Ortika a, Casey L. Pell a,
Monica L. Nation a, Ahmed Alamrousi a, Jason Hinds e,f, Sodbayar Demberelsuren g, Cattram Nguyen a,b,
Tuya Mungun c, E. Kim Mulholland a,b,h,2, Catherine Satzke a,b,i,2
aNew Vaccines, Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Australia
bDepartment of Paediatrics, The University of Melbourne, Parkville, Australia
cNational Center of Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia
dMinistry of Health, Ulaanbaatar, Mongolia
e Institute for Infection and Immunity, St George’s, University of London, London, UK
fBUGS Bioscience, London Bioscience Innovation Centre, London, UK
g Expanded Programme on Immunization, World Health Organization, Ulaanbaatar, Mongolia
hDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
iDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Australia
a r t i c l e i n f oArticle history:
Received 18 February 2019
Received in revised form 24 May 2019
Accepted 26 May 2019
Available online xxxx
Keywords:
13-valent pneumococcal conjugate vaccine
impact
Pneumococcal carriage
Children
Mongolia
Herd immunity
Antimicrobial resistancea b s t r a c t
Background: Nasopharyngeal carriage of Streptococcus pneumoniae precedes disease, is the source of
pneumococcal community spread, and the mechanism for herd protection provided by pneumococcal
conjugate vaccines (PCVs). There are few PCV impact studies in low- and middle-income countries, par-
ticularly in Asia. In 2016, Mongolia introduced the 13-valent PCV (PCV13) in a phased manner using a 2
+ 1 schedule, with catch-up. We aimed to assess the impact of PCV13 introduction on nasopharyngeal
pneumococcal carriage and density in children in Mongolia.
Methods: We conducted two cross-sectional carriage surveys (pre- and one year post-PCV) at community
health clinics in two districts of the capital city, Ulaanbaatar in both May-July 2015 and 2017. The study
analysis included 961 children too young to be vaccinated (5–8 weeks old) and 989 children eligible for
vaccination (12–23 months old). Pneumococci were detected by quantitative real-time PCR and molecu-
lar serotyping performed using DNA microarray.
Findings: One year post-PCV introduction, PCV13 serotype carriage reduced by 52% in 12–23 month olds
(adjusted prevalence ratio [aPR] 0.48 [95% confidence interval [CI] 0.39–0.59]), with evidence of non-
PCV13 serotype replacement (aPR 1.55 [95% CI 1.30–1.85]), compared with the pre-PCV period. In 5–
8 week olds, PCV13 serotype carriage reduced by 51% (aPR 0.49 [95% CI 0.33–0.73]) with no significant
change in non-PCV13 serotype carriage (aPR 1.10 [95% CI 0.83–1.46]). An increase was observed in both
PCV13 and non-PCV13 pneumococcal density post-PCV introduction. Antimicrobial resistance (AMR)
genes were common, with 82.3% of samples containing at least one of the 10 AMR genes assessed.
Conclusion: This study demonstrates substantive PCV13 impact on pneumococcal carriage one year post-
vaccine introduction in Mongolia. The reductions in PCV13 serotype carriage are likely to result in reduc-
tions in pneumococcal disease including indirect effects. Increases in non-PCV13 serotypes require fur-
ther monitoring.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Streptococcus pneumoniae (the pneumococcus) remains an
important cause of childhood mortality in the post-
pneumococcal conjugate vaccine (PCV) period, causing annd one
2 C. von Mollendorf et al. / Vaccine xxx (xxxx) xxxestimated 318,000 deaths globally in children aged 1–59 months in
2015 [1]. Pneumococcal carriage is considered a prerequisite for
disease [2] and the source of community pneumococcal spread.
Children vaccinated with PCV are less likely to carry vaccine sero-
types, and therefore less likely to transmit these serotypes to
unvaccinated individuals [3], resulting in indirect effects [4]. There
are limited data on herd protection for infants too young to be vac-
cinated [5,6]. Over time, elimination of vaccine serotypes results in
serotype replacement, with increased colonization and disease due
to non-vaccine serotypes [7]. Serotype replacement may erode the
public health benefit provided by PCV [7,8].
In settings with limited invasive pneumococcal disease (IPD)
surveillance to measure vaccine impact, carriage is a valid alterna-
tive approach to demonstrate PCV effects [9]. PCV introduction
reduces antimicrobial resistance in some settings, as vaccine sero-
types are more likely to be resistant compared with non-vaccine
serotypes [10]. Although there is increasing evidence documenting
the importance of pneumococcal nasopharyngeal density on dis-
ease and transmission, the effect of PCVs on pneumococcal density
is largely unknown [6,11–13]. PCVs have been introduced into the
national immunization programmes of 59 low- and middle-income
countries (LMICs) as part of the Gavi pneumococcal Advance Mar-
ket Commitment funding scheme [14]. There are limited data on
vaccine impact using carriage data in LMIC settings, particularly
from Asia.
The study aim was to investigate the impact of 13-valent PCV
(PCV13) introduction in Mongolia on pneumococcal carriage using
two cross-sectional community carriage surveys, conducted
pre- and one year post-PCV13 introduction in children aged
12–23 months and 5–8 weeks. These age groups were selected to
represent vaccine-eligible children and young, unvaccinated
infants, respectively.2. Methods (see supplement for full details of laboratory
methods)
2.1. Study site
Mongolia is a middle-income landlocked country in Central Asia
with an estimated population of 3 million. The capital city, Ulaan-
baatar, is divided into nine districts. From 2016, the Government of
Mongolia introduced PCV13 in a phased manner (by district) into
the routine immunization schedule at 2, 4 and 9 months of age.
PCV was introduced into the two study districts in Ulaanbaatar
(Songinokhairkhan and Sükhbaatar) in June 2016 with a catch-up
campaign for children 3 to 23 months of age (given two doses of
PCV13, two months apart).2.2. Study design and participants
Cross-sectional carriage surveys were conducted at family
health centres in the two districts from May-July in both 2015
(pre-PCV introduction) and 2017 (one year post-PCV introduction).
The study districts included 51 subdistricts; each subdistrict has a
family health centre and is defined by a predominant housing type.
Family health centres were randomly selected stratified by pre-
dominant subdistrict housing type: apartment, ger (traditional
portable dwelling) and mixed. Where insufficient patient numbers
were available in a given health centre, children were recruited
from other health centres in the same district with a similar profile.
Similar numbers of children were enrolled from the 5–8 week and
12–23 month age group from a total of 23 clinics in 2015 and 32
clinics in 2017.
Caregivers of children within the two age groups were con-
tacted by telephone to attend the clinic for the study if they werePlease cite this article as: C. von Mollendorf, E. M. Dunne, S. La Vincente et al., P
year after the introduction of the 13-valent pneumococcal conjugate vaccine,willing. Children in the eligible age groups who were attending the
clinics for immunization or other routine well-child clinic visits
were also invited to participate. Children were ineligible if they
had a fever (>37 C), had not lived in the area for at least three con-
secutive months, or if they were 5–8 weeks old and had received
PCV13. Clinicians actively excluded children with respiratory
symptoms. Study staff completed a questionnaire documenting
potential risk factors for pneumococcal carriage. PCV13 vaccina-
tion status was verified using the child’s hand held vaccination
card and confirmed against the electronic immunization register
[15].
2.3. Sample size
Sample size calculations assumed that with a baseline PCV13
serotype carriage prevalence of 16%, 281 participants in each age
group would detect a 50% reduction, with 90% power at a 5% signif-
icance level. As the true prevalence in Mongolia was unknown, the
sample size for each age group was increased to 500 per survey.
2.4. Ethics approval
The study was approved by the Mongolian Ministry of Health
National Ethics Committee for Health Research and the Royal Chil-
dren’s Hospital Human Research Ethics Committee (HREC 33203A).
Written informed consent was obtained from parents/caregivers
for all children prior to any study procedures being conducted.
2.5. Sample collection and laboratory procedures
We used World Health Organization recommended methods
[16] for nasopharyngeal sample collection, handling and transport.
Pneumococcal detection, quantification by real-time PCR, and
molecular serotyping by DNA microarray was carried out as previ-
ously described [17,18]. Samples that were lytA qPCR positive (Ct
value <35) but not able to be serotyped (either culture negative
or low DNA yield from culture) were considered pneumococcal
positive, serotype unknown [17]. PCV13 serotypes were defined
as 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. All other ser-
otypes, including non-encapsulated pneumococci as described by
Salter et. al. [19], were designated non-PCV13 serotypes. The
microarray can detect and discriminate seven genetic variants of
non-encapsulated pneumococci [18,19].
The microarray detects 10 antimicrobial resistance (AMR)
genes. To examine the presence of AMR genes, we restricted the
analysis to samples containing a single pneumococcal type with
no other species identified.
2.6. Statistical analysis
Questionnaires were double entered into Microsoft Access data-
bases. The two databases were compared, cleaned and analysed
using Stata version 15.1 (College Station, TX: StataCorp LLC). A
chi-squared test was used to compare categorical data and the
Mann-Whitney test for continuous data.
Univariate log-binomial regression was used to determine asso-
ciations between overall pneumococcal carriage and potential con-
founders. Variables with a p-value <0.20 were included in log-
binomial regression models for multivariable analysis to estimate
adjusted prevalence ratios. All non-significant factors (assessed at
p-value >0.05) were dropped from the multivariable models
employing stepwise regression starting with predictors with the
highest p-values. Reductions in PCV13 carriage were calculated
as (1  aPR) * 100%, while an increase in non-PCV13 carriage was
reported as a fold increase. We used logistic regression to explore
risk factors for overall pneumococcal carriage in both age groups asneumococcal carriage in children in Ulaanbaatar, Mongolia before and one
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Table 1
Characteristics of study participants in cross-sectional pneumococcal carriage
surveys, performed pre- and one year post-PCV13 (2015 and 2017 respectively), in
healthy children in Mongolia, by age group and time period.
5–8 week old infants Pre-PCV13
N = 461a
Post-PCV13
N = 500a
p-value
Median age in weeks (IQR)b 6.4 (5.3–7.7) 6.1 (5.4–7.0) 0.05
Female sex, n (%) 222 (48) 244 (49) 0.84
Parent primary caregiver, n (%) 457 (99) 495 (99) 0.83
2 children <5 years in household,
n (%)
177 (38) 217 (44) 0.11
Exposure to household cigarette
smoke, n (%)
28/441 (6) 33 (7) 0.88
Mother completed university, n (%) 260/455
(57)
287/499
(58)
0.91
Crowdingc, n (%) 172 (37) 172 (34) 0.35
Above minimum incomed, n (%) 287/435
(66)
188/489
(39)
<0.001
Born by caesarean section, n (%) 141/457
(31)
147 (29) 0.62
Breastfeeding at time of survey,
n (%)
439 (95) 482 (96) 0.36
C. von Mollendorf et al. / Vaccine xxx (xxxx) xxx 3the log-binomial regression model did not converge for the older
age group.
Bacterial density data were log10 transformed and reported as
log10 genome equivalents/ml (log10 GE/ml). Median carriage densi-
ties were calculated for vaccinated (1 PCV13 doses) and unvacci-
nated 12–23 month old children (0 doses of PCV13), with
unvaccinated children from the post-PCV13 period excluded from
the analysis. Median densities were compared using quantile
regression to determine the impact of PCV13 on pneumococcal
density. Median quantile regression estimates the median of the
dependent variable (pneumococcal density), conditional on the
value of the independent variable (PCV13 vaccination). With a bin-
ary predictor, the regression coefficient is the difference in medi-
ans between unvaccinated and vaccinated children. No variables
were found to be significantly associated with density (assessed
at p-value <0.05) and unadjusted results are presented. When the
analysis was performed including unvaccinated children from the
post-PCV period in the comparison group the results were very
similar (data not shown).Living in informal housing (ger),
n (%)
153 (33) 154 (31) 0.43
Member of household treated for
tuberculosis
15 (3) 12 (2) 0.42
Main source of cooking fuel, n (%)
Electricity 184 (40) 228 (46) 0.002
Coal 253 (55) 239 (48)
Wood 16 (4) 33 (7)
Gas 5 (1) 0 (0)
Other 3 (1) 0 (0)
Previous admission for pneumonia,
n (%)
7/457 (2) 7 (1) 0.87
12–23 month old children Pre-PCV13
N = 489a
Post-PCV13
N = 500a
p-value
Median age in weeks (IQR)b 16.4 (14.1–
20.7)
15.9 (14.1–
19.5)
0.10
Female sex, n (%) 257 (53) 241 (48) 0.17
Parent primary caregiver, n (%) 410 (84) 423 (85) 0.75
2 children <5 years in household,
n (%)
156 (32) 183 (37) 0.12
Exposure to household cigarette
smoke, n (%)
55/488 (11) 54 (11) 0.81
Mother completed university, n (%) 283/487
(58)
296 (59) 0.73
Crowdingc, n (%) 206 (42) 176 (35) 0.03
Above minimum incomed, n (%) 277/465
(60)
188/486
(39)
<0.001
Born by caesarean section, n (%) 142 (29) 161 (32) 0.29
Breastfeeding at time of survey,
n (%)
329 (67) 341 (68) 0.76
Living in informal housing (ger),
n (%)
189 (39) 156 (31) 0.01
Member of household treated for
tuberculosis
19 (4) 6 (1) 0.007
Main source of cooking fuel, n (%)
Electricity 186 (38) 218 (44) 0.001
Coal 279 (57) 230 (46)
Wood 16 (3) 37 (7)
Gas 2 (0.4) 1 (0.2)
Other 6 (1) 14 (3)
Previous admission for pneumonia,
n (%)
124 (25) 126 (25) 0.95
Vaccinated with any number of
PCV13 doses
Received 1 dose, n (%) 0 (0) 21/439 (5)
Received 2 doses, n (%) 0 (0) 339/439
(77)
Received 3 doses, n (%) 0 (0) 79/439 (18)
a Total unless otherwise indicated.
b IQR = Interquartile range.
c Three or more people per room.
d The definition of minimum living standard was changed by the Government of
Mongolia between 2015 (170,000₮ per person/per month) and 2017 (241,000₮ per
person/per month). This likely accounts for the some of the reduction in people
earning above the standard in 2017.3. Results
3.1. Participant characteristics
There were 2000 children enrolled; 50 children did not meet
the age inclusion criteria in 2015 and were excluded from the anal-
ysis. Characteristics of the 1950 eligible children were similar
between the two survey years, with the exception of crowding,
income, electricity usage, and housing (Table 1). In the post-
PCV13 survey, 84% (418/500) of participants aged 12–23 months
had received two or more doses of PCV. No 5–8 week old infants
were PCV-vaccinated in either year.
3.2. Risk factors for pneumococcal carriage
On multivariable analysis, risk factors for overall pneumococcal
carriage were similar in both age groups in both years (Supplemen-
tary Table S1). Living in a ger, and the presence of multiple children
aged under 5 years in the household were associated with pneu-
mococcal carriage, whereas higher maternal education was associ-
ated with a lower likelihood of carriage in children. Exposure to
household cigarette smoke was associated with pneumococcal car-
riage in the post-PCV period only.
3.3. Carriage prevalence in the pre- and post-PCV period
There was no change in overall pneumococcal carriage preva-
lence in either age group (Table 2). In children aged 12–23 months,
there was a 52% reduction in PCV13 serotype carriage (adjusted
prevalence ratio [aPR] 0.48 [95% confidence interval [CI] 0.39–
0.59]), with evidence of serotype replacement (1.6 fold increase
in non-PCV13 serotypes; aPR 1.55 [95% CI 1.30–1.85]). In 5–8 week
old infants there was a 51% reduction in PCV13 serotype carriage
(aPR 0.49 [95% CI 0.33–0.73]) compared with the pre-PCV period;
there was no change in non-PCV13 serotype carriage prevalence
(aPR 1.10 [95% CI 0.83–1.46]).
3.4. Serotypes over time
Serotyping results were obtained from 811 of 824
pneumococcal-positive samples. Thirteen samples were not able
to be serotyped because they were either culture negative
(n = 12) or had a low DNA yield from culture (n = 1). A total of
997 pneumococci were identified, 861 capsular pneumococci,Please cite this article as: C. von Mollendorf, E. M. Dunne, S. La Vincente et al., Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one
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Table 2
Carriage prevalence and prevalence ratios for pneumococcal carriage (overall, PCV13 serotypes, and non-PCV13 serotypes) for 5–8 week old infants and 12–23 month old children
before (2015) and one year after (2017) PCV13 introduction.
Pre-PCV13 n/N Pre-PCV13 prevalence
(%) (95% CI)
Post-PCV13
n/N
Post-PCV13 prevalence
(%) (95% CI)
Unadjusted prevalence
ratio (95% CI)
Adjusted prevalence
ratioa (95% CI)
Overall pneumococcib
5–8 week old 131/461 28.4 (24.3–32.8) 120/500 24.0 (20.3–28.0) 0.84 (0.68–1.04) 0.86 (0.70–1.05)
12–23 month old 294/489 60.1 (55.6–64.4) 279/499 55.9 (51.4–60.3) 0.93 (0.84–1.03) 0.96 (0.87–1.05)
PCV13 serotypes
5–8 week old 59/457 12.9 (10.0–16.3) 31/494 6.3 (4.3–8.9) 0.49 (0.32–0.74) 0.49 (0.33–0.73)
12–23 month old 206/488 42.2 (37.8–46.7) 98/497 19.7 (16.3–23.5) 0.47 (0.38–0.57) 0.48 (0.39–0.59)
Non-PCV13 serotypes
5–8 week old 74/457 16.2 (12.9–19.9) 86/494 17.4 (14.2–21.0) 1.08 (0.81–1.43) 1.10 (0.83–1.46)
12–23 month old 129/488 26.4 (22.6–30.6) 200/497 40.2 (35.9–44.7) 1.52 (1.27–1.83) 1.55 (1.30–1.85)
a The following variables were used to adjust the prevalence ratios in each group: Overall pneumococcal group (two or more children under five years in the household,
housing type, mother’s education; cooking fuel); PCV13 serotype group (two or more children under five years in the household, housing type, member of household treated
for tuberculosis); non-PCV13 serotype group (two or more children under five years in the household, housing type, mother’s education) using multivariable log binomial
regression models.
b Overall carriage prevalence does not necessarily equal the sum of PCV13 serotype and non-PCV13 serotype prevalence. This is due to multiple serotype carriage and/or
exclusion of pneumococcal-positive samples for which the serotype was not determined.
4 C. von Mollendorf et al. / Vaccine xxx (xxxx) xxxand 136 non-encapsulated pneumococci representing four differ-
ent genetic variants [19]. All PCV13 serotypes were detected,
although serotype 1 (n = 2) and 5 (n = 1) were rare.
Fig. 1A shows carriage prevalence of PCV13 serotypes and the
most common non-PCV13 serotypes in infants 5–8 weeks, pre-
and post-PCV13 introduction. In infants 45% (59/131) of pneumo-
cocci were PCV13 serotypes in the pre-PCV13 period, compared
with 26% (31/120) in the post-PCV13 period (p = 0.002). The most
common serotypes carried in the pre-PCV13 period were 19F
(n = 13), 23F (n = 13) and non-encapsulated NT2 (n = 12); while
in the post-PCV13 period, serotypes 15A (n = 11) and 23A
(n = 11) predominated. PCV13 serotype 23F decreased between
the pre-PCV13 (13/457 [2.8%]) and post-PCV13 survey (3/494
[0.6%], p = 0.007), while carriage prevalence of non-PCV13 sero-
types 15A and 23A were higher in the post-PCV13 survey (both
11/494 [2.2%]) compared with the pre-PCV13 survey (both 2/457
[0.4%], p = 0.02).
For children aged 12–23 months (Fig. 1B), 206/294 (70.1%) of
pneumococci were PCV13 serotypes in the pre-PCV13 survey, com-
pared with 98/279 (35.1%) post-PCV13 introduction (p < 0.001).
The most common serotypes identified in 2015 were 6A (n = 61),
19F (n = 47), non-encapsulated NT2 (n = 30) and 23F (n = 29) com-
pared with 19F (n = 41), 15A (n = 36), 34 (n = 34) and 15B/C
(n = 26) in 2017. PCV13 serotypes 23F and 6A decreased between
the pre-PCV13 (29/488 [5.9%] and 61/488 [12.5%], respectively)
and post-PCV13 survey (12/497 [2.4%], p = 0.005 and 17/497
[3.4%], p < 0.001, respectively). Similarly, serotypes 14 (p < 0.001)
and 6B (p = 0.02) were significantly reduced post-PCV introduc-
tion. Interestingly, PCV13 serotypes 19F (47/488 [9.6%] to 41/497
[8.2%], p = 0.44) and 19A (13/488 [2.7%] to 8/497 [1.6%], p = 0.25)
showed no significant reduction. Non-PCV13 serotypes 15A and
34 increased in the post-PCV13 survey (36/497 [7.2%] and
34/497 [6.8%], respectively) compared with the pre-PCV13
survey (3/488 [0.6%] and 7/488 [1.4%], respectively, both
p-values < 0.001).
Most pneumococcal-positive samples contained a single sero-
type (666/811, 82.1%). Less than 10% of colonized infants aged
5–8 weeks (21/241, 8.7%) carried more than one serotype, while
21.8% (124/570) of older colonized children carried two to four ser-
otypes. The proportion of children with multiple serotype carriage
did not differ significantly pre- and post-PCV13 introduction: 2.7%
and 1.8% (p = 0.37) for 5–8 week old infants; and 13.1% and 12.1%
(p = 0.62) for 12–23 month old children, respectively.Please cite this article as: C. von Mollendorf, E. M. Dunne, S. La Vincente et al., P
year after the introduction of the 13-valent pneumococcal conjugate vaccine,3.5. Antibiotic resistance genes
AMR genes were common, with 82.3% of samples containing at
least one of the 10 AMR genes assessed. Samples with a PCV13 ser-
otype were more likely to have at least one AMR gene detected
(95.0%, 264/278), compared with samples with non-PCV13 sero-
types (71.0%, 220/310) (Supplementary Table S2). Four AMR genes
were significantly more common in PCV13 serotypes (N = 278)
compared with non-PCV13 serotypes (N = 310); tetM 258 (92.8%)
versus 189 (61.0%), cat 87 (31.3%) versus 52 (16.8%), mefA 138
(49.6%) versus 62 (20.0%) and ermB 199 (71.6%) versus 128 (41.3%).
In children 12–23 months, the proportion of samples containing
cat decreased post-PCV13 (54/204, 26.5% to 26/189, 13.8%), likely
due to decreases in PCV13 serotypes carrying this gene; no signif-
icant changes were observed in infants (Supplementary Table S3).3.6. Pneumococcal densities
The density of pneumococcal carriage for overall pneumococci,
PCV13 serotypes, and non-PCV13 serotypes were significantly
higher in the post-PCV13 period compared with the pre-PCV13
period for both age groups (all p-values < 0.001, Fig. 2A/B). In 12–
23 month old children, the median density of overall pneumococci,
PCV13 and non-PCV13 serotypes was higher in PCV13 vaccinated
(1 dose) compared with unvaccinated (0 doses) children
(Table 3).4. Discussion
There are limited data on PCV impact from LMICs in Asia. We
demonstrated a substantial impact of PCV13 introduction in
healthy children in Mongolia, one year post-introduction. PCV13
serotype carriage was reduced by more than 50% in children aged
12–23 months and unvaccinated 5–8 week old infants. Indirect
protection is particularly important in young infants, as they are
at high risk for bacterial infections, and the case fatality rate for
pneumococcal infections in neonates is high [20].
Characteristics of children were similar between the two survey
years, with the exception of crowding, housing, electricity usage,
and income. The reduction in the proportion of households earning
above minimum income level between the two years was likely inneumococcal carriage in children in Ulaanbaatar, Mongolia before and one
Vaccine, https://doi.org/10.1016/j.vaccine.2019.05.078
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Fig. 1. Carriage prevalence of PCV13 serotypes and the most common non-PCV13 serotypes in (A) 5–8 week old infants and (B) 12–23 month old children, before (pre-PCV13)
or after (post-PCV13) vaccine introduction. Solid bars indicate carriage that was detected as a single or major (dominant) serotype, open bars indicate carriage that was
detected as a minor (second or third) serotype. Serotypes 15B and 15C were reported as 15B/C [39] and serotype 11F-like were grouped together with 11A serotypes [40]. NT2
refers to non-encapsulated pneumococci containing nspA/pspK [19]. Significant differences between pre-/post-periods are indicated with an asterisk.
C. von Mollendorf et al. / Vaccine xxx (xxxx) xxx 5part due to the definition change in minimum living standard in
2017 by the Government of Mongolia.
Most published studies on the effect of PCV introduction are
from higher income countries, focus on hospitalized children and
in the case of PCV13 introduction had preceding PCV7. Previous
work by our group examined community impact of PCV13 on
nasopharyngeal carriage in Lao PDR two years following introduc-
tion (3 + 0 schedule with limited catch-up) [17], finding a 23%
reduction in carriage prevalence of PCV13 serotypes with no
significant difference in non-PCV13 serotypes in vaccinated
12–23 month old children, and suggestive but non-significant
changes in 5–8 week old infants [17]. Other published work from
Greenland (2 + 1 schedule) showed a 56% reduction in PCV13 ser-
otype carriage three years post-PCV13 introduction, compared
with one year post introduction [21]. In LMICs four published
studies described PCV10 effects on carriage in non-hospitalizedPlease cite this article as: C. von Mollendorf, E. M. Dunne, S. La Vincente et al., P
year after the introduction of the 13-valent pneumococcal conjugate vaccine,children without prior PCV7 use. A cross-sectional carriage study
in Kenya (3 + 0 schedule with catch-up) showed a reduction of
PCV10 serotype carriage in individuals aged <5 years by 64% two
years post-introduction [22]. In Brazil (3 + 1 schedule with catch-
up), a 91% reduction in PCV10 serotype carriage in children 12–
23 months of age was observed three years following introduction
[23]. In Fiji, (3 + 0 schedule with no catch-up) PCV10 carriage in 5–
8 week old unvaccinated infants and 12–23 month old children
declined by 44% and 66% respectively three years following
PCV10 introduction [18]. Lastly, in Mozambique (3 + 0 schedule
with no catch-up) PCV10 carriage declined by 42% in HIV-
uninfected vaccinated children aged <5 years less than two years
post-PCV10 introduction [24].
Even though our study was only one year post-PCV introduc-
tion, we showed stronger reductions than Lao PDR, and similar
reductions to some of the PCV10 studies that were conductedneumococcal carriage in children in Ulaanbaatar, Mongolia before and one
Vaccine, https://doi.org/10.1016/j.vaccine.2019.05.078
Fig. 2. Nasopharyngeal pneumococcal carriage density (log10 genome equivalents/
ml) in (A) 5–8 week old infants and (B) 12–23 month old children who were
positive for pneumococcal carriage. Boxes depict interquartile range (IQR) with a
central line at the median, and whiskers extend 1.5 times IQR past the quartiles.
Values outside whiskers plotted as individual points. For both age groups, the
median density of overall pneumococci, PCV13 serotypes, and non-PCV serotypes
was higher post-PCV13 compared with pre-PCV13 introduction (p < 0.001).
6 C. von Mollendorf et al. / Vaccine xxx (xxxx) xxxtwo or more years post-introduction. Differences in the extent of
PCV impact on carriage reduction are likely impacted by a number
of factors including number of years’ post-PCV introduction, differ-
ences in baseline demographics, baseline serotype distribution,
vaccination schedule, catch-up campaigns and PCV coverage. OfTable 3
Median density and quantile regression analysis of overall pneumococci, PCV13 serotypes,
12–23 month old children who were pneumococcal carriers in 2015 and 2017.
Median density (IQR)a
Overall pneumococci
Unvaccinated (294)d 5.04 (4.10, 5.76)
PCV13 vaccinated (239)d 5.87 (5.10, 6.56)
PCV13 serotypes
Unvaccinated (206)d 5.11 (4.23, 5.76)
PCV13 vaccinated (78)d 5.80 (4.78, 6.51)
Non-PCV13 serotypes
Unvaccinated (129)d 4.79 (4.02, 5.67)
PCV13 vaccinated (178)d 5.83 (5.08, 6.51)
a Density reported in log10 genome equivalents/ml and interquartile range (IQR).
b Unadjusted coefficient (difference in medians) as determined by quantile regression
c P-value refers to difference in median densities between vaccinated and unvaccinat
d Number of pneumococcal carriers shown in parentheses. Unvaccinated children onl
who had received one or more doses of vaccine.
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year after the introduction of the 13-valent pneumococcal conjugate vaccine,note, there is high PCV13 coverage in Mongolia (estimated at
97% in 2017 [25]) and extensive catch-up campaigns in children
up to 24 months of age were conducted in the two study districts.
Although PCV13 has been shown to generate good functional
antibody responses against 19F and 19A [26], we observed very lit-
tle reduction in these two serotypes; however variable reductions
have been seen for 19A [27,28] and 19F [18] carriage in other
studies.
Our results are consistent with other studies demonstrating ser-
otype replacement in carriage in vaccinated children [22,23]. Non-
vaccine serotypes 15A, 15B/C and 34 increased post-introduction
in our older age group, while in the 5–8 week infants 15A and
23A increased. Increases in nasopharyngeal carriage of non-
PCV13 serotypes were shown in healthy US children aged
6–30 months in the 5 years following PCV13 introduction [29].
Serotypes 15A and 23B have been shown to cause increases in
IPD post-PCV13 introduction [30]. Even though there was no
change in overall carriage prevalence of non-PCV13 serotypes in
the 5–8 week olds in our study, we expect that this will increase
over time.
The proportion of children with multiple serotype carriage was
low in our study, and we did not find any changes in multiple ser-
otype carriage following the introduction of PCV, which is similar
to some previous studies [17,31].
We identified a number of risk factors for pneumococcal car-
riage which were similar to previous studies. This included the
presence of multiple children under the age of 5 years in the
household [32] and exposure to cigarette smoke in the household
[33].
In many Asian countries, community usage of antibiotics results
in high levels of AMR [34] and data from Mongolia are consistent.
Inappropriate prescription of antibiotics for pneumonia [35] and
high antibiotic resistance in ICU patients [36] has been shown. In
our study, 82% of pneumococcal positive samples had at least
one AMR gene, with a higher proportion of four AMR genes in
PCV13 serotypes than non-vaccine serotypes. PCV-mediated
effects on AMR in Mongolia may be less than those observed in
other settings [10] given the high background level of circulating
AMR genes. Analysis of AMR genes in our study was limited to
the 10 mobile-genetic element associated genes included on the
microarray, and some antibiotics of clinical importance, such as
penicillin, were not assessed, nor was phenotypic testing
conducted.
This study showed an increase in both PCV13 and non-PCV13
density post-PCV introduction. Some studies [6,11–13,17,18] have
evaluated PCV impact on pneumococcal density, with varying
results, but methodology and study timing differed. These include
a cluster-randomized trial in The Gambia which showed a declineand non-PCV13 serotypes in PCV13 vaccinated (1 dose) and unvaccinated (0 doses)
Unadjusted coefficient (95% CI)b p-valuec
Reference
0.83 (0.55–1.10) <0.001
Reference
0.65 (0.23–1.06) 0.002
Reference
1.08 (0.72–1.44) <0.001
, reported with 95% confidence intervals (CI).
ed groups.
y included those from the pre-PCV13 period. Vaccinated children included children
neumococcal carriage in children in Ulaanbaatar, Mongolia before and one
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C. von Mollendorf et al. / Vaccine xxx (xxxx) xxx 7in vaccine and non-vaccine serotype density in vaccinated and con-
trol villages [13], and a study from Lao PDR [17] which found that
both VT and NVT pneumococcal density increased post-PCV intro-
duction, which was thought to be due to temporal variation and/or
secular trends. All the available literature does not show a consis-
tent long-term effect of PCV on pneumococcal density.
This study has some limitations. Firstly, older age groups were
not included, however we would expect to see indirect effects of
PCV introduction as observed in other settings [37]. Secondly, our
study had a relatively short follow-up post-PCV introduction, and
so an effect on pneumococcal density may not yet be apparent
[24]. Lastly, it is possible that information on all relevant con-
founders influencing the vaccine type carriage endpoint were not
collected in this study. This study also has a number of strengths.
Firstly, we sampled clinics randomly according to subdistrict to
be representative of the different housing types in Ulaanbaatar,
including to account for difference in health seeking behaviour.
Therefore, it is likely that our findings are generalizable to other
urban populations in Mongolia. Secondly, we used sensitive molec-
ular methods [16,38] to measure the prevalence and density of
pneumococcal carriage, and were able to detect all pneumococcal
serotypes present in a sample. Although carriage does not measure
the impact of PCV on disease, it is a practical and biologically rele-
vant end-point, with surveys able to be implemented quickly
ahead of vaccine introduction. Thirdly, due to the high vaccine cov-
erage achieved by the routine and catch-up campaigns for PCV, we
were able to demonstrate evidence of PCV impact and serotype
replacement one year following PCV13 introduction in Mongolia.
5. Conclusion
This study provides evidence of substantial PCV impact follow-
ing introduction in a middle income country in Asia. The reduction
in PCV13 serotype carriage will likely result in decreases in pneu-
mococcal disease in both vaccine-eligible and unvaccinated age
groups. Serotype replacement warrants ongoing monitoring.
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